Baker Avenue Asset Management, LP Vaxcyte, Inc. Transaction History
Baker Avenue Asset Management, LP
- $5.03 Billion
- Q3 2025
A detailed history of Baker Avenue Asset Management, LP transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Baker Avenue Asset Management, LP holds 13,143 shares of PCVX stock, worth $548,194. This represents 0.01% of its overall portfolio holdings.
Number of Shares
13,143
Previous 13,143
-0.0%
Holding current value
$548,194
Previous $427,000
10.77%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding PCVX
# of Institutions
322Shares Held
139MCall Options Held
229KPut Options Held
160K-
Janus Henderson Group PLC London, X014.7MShares$613 Million0.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$500 Million0.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA12MShares$499 Million8.5% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$415 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6MShares$250 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $2.47B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...